Next-generation sequencing using microfluidic PCR enrichment for molecular autopsy

  • Hariharan Raju (Creator)
  • James S. Ware (Creator)
  • Jonathan R. Skinner (Creator)
  • Paula L. Hedley (Creator)
  • Gavin Arno (Creator)
  • Donald R. Love (Creator)
  • Christian Van Der Werf (Contributor)
  • Jacob Tfelt-hansen (Creator)
  • Bo Gregers Winkel (Creator)
  • Marta C. Cohen (Creator)
  • Xinzhong Li (Contributor)
  • Shibu John (Contributor)
  • Sanjay Sharma (Creator)
  • Steve Jeffery (Creator)
  • Arthur A. M. Wilde (Creator)
  • Michael Christiansen (Creator)
  • Mary N. Sheppard (Creator)
  • Elijah R. Behr (Creator)



Abstract Background We aimed to determine the mutation yield and clinical applicability of “molecular autopsy” following sudden arrhythmic death syndrome (SADS) by validating and utilizing low-cost high-throughput technologies: Fluidigm Access Array PCR-enrichment with Illumina HiSeq 2000 next generation sequencing (NGS). Methods We validated and optimized the NGS platform with a subset of 46 patients by comparison with Sanger sequencing of coding exons of major arrhythmia risk-genes (KCNQ1, KCNH2, SCN5A, KCNE1, KCNE2, RYR2). A combined large multi-ethnic international SADS cohort was sequenced utilizing the NGS platform to determine overall molecular yield; rare variants identified by NGS were subsequently reconfirmed by Sanger sequencing. Results The NGS platform demonstrated 100% sensitivity for pathogenic variants as well as 87.20% sensitivity and 99.99% specificity for all substitutions (optimization subset, n = 46). The positive predictive value (PPV) for NGS for rare substitutions was 16.0% (27 confirmed rare variants of 169 positive NGS calls in 151 additional cases). The overall molecular yield in 197 multi-ethnic SADS cases (mean age 22.6 ± 14.4 years, 68% male) was 5.1% (95% confidence interval 2.0–8.1%), representing 10 cases carrying pathogenic or likely pathogenic risk-mutations. Conclusions Molecular autopsy with Fluidigm Access Array and Illumina HiSeq NGS utilizing a selected panel of LQTS/BrS and CPVT risk-genes offers moderate diagnostic yield, albeit requiring confirmatory Sanger-sequencing of mutational variants.
Date made available23 Jul 2019
  • Next-generation sequencing using microfluidic PCR enrichment for molecular autopsy

    Raju, H., Ware, J. S., Skinner, J. R., Hedley, P. L., Arno, G., Love, D. R., Van Der Werf, C., Tfelt-hansen, J., Winkel, B. G., Cohen, M. C., Li, X., John, S., Sharma, S., Jeffery, S., Wilde, A. A. M., Christiansen, M., Sheppard, M. N. & Behr, E. R., 23 Jul 2019, In: BMC Cardiovascular Disorders. 19, 1, p. 174

    Research output: Contribution to journalArticlepeer-review

    Open Access
    95 Downloads (Pure)

Cite this